Navigation Links
Ranbaxy gets US FDA approval for Lisinopril

Ranbaxy Pharmaceuticals Inc (RPI) has received a tentative approval from the US FDA for Lisinopril tablets. Lisinopril is recommended for hypertension, either alone for initial therapy or with other classes of anti-hypertenive agents. It is also used as adjunctive therapy in the management of heart failure and patients who do not respond to diuretics. //

However it expects to launch the product only in June 2002, when the original patent expires on the drug, Zestril. Zestril is a registered trademark of Astra Zeneca UK Ltd. A wholly-owned subsidiary of Ranbaxy Laboratories Ltd, RPI expects to be able to access retail pharmacy outlets, wholesalers, hospitals and generic distributors in the US, only post - June 2002.

Sales in 2000 for Lisinopril touched $ 1.2 billion. It is sold under two brands in the US market , of which Zestril alone sold $ 0.66 billion in 2000. The tentative approval has been given for a single entity form of Lisinopril. An Abbreviated New Drug Application (ANDA) submission by Ranbaxy, for Lisinopril and Hydrochlorithizide is still outstanding and pending approval from the US FDA.

The tentative US FDA approval has been given for Lisinopril tablets USP 2.5 mg, 5 mg, 10 mg 20 mg and 40 mg. Based on kinetic studies, it has been deemed to be a bio-equivalent and therapeutically equivalent to Zestril tablets. The tentatively approved formulation is the result of R&D efforts that focussed on the Active Pharmaceutical Ingredient and the bio-equivalent formulation, both of which were developed in-house.


Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy Labs Entry Into Anti-Acne Market
3. Ranbaxy trying to make inroads in herbal drugs market
4. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
5. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
6. Ranbaxy opens Drug discovery centre in Gurgaon
7. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
8. SRL Ranbaxy offers quicker bird flu diagnostic test
9. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
10. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:

(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: